United StatesBreaking News

Paychex (NASDAQ:PAYX) reported fourth-quarter fiscal 2026 revenue of $1.61 billion, reflecting a 12% increase compared with the same period last year.

InMode (NASDAQ:INMD) said its board received an unsolicited proposal on June 17, 2026 from M.N. Business Strategy to acquire all outstanding ordinary shares it does not already own for $16.20 per share in cash.

Kaspi.kz (NASDAQ:KSPI) received regulatory approval from Türkiye’s Banking Regulation and Supervision Agency (BDDK) to acquire Rabobank A.Ş., a fully licensed Turkish bank.

EXL Service Holdings (NASDAQ:EXLS) signed a definitive agreement to acquire iMerit, a company specializing in AI model training, evaluation, and reinforcement learning services, in a transaction valued at up to $310 million.

Qualcomm Incorporated (NASDAQ:QCOM) has reached an agreement to acquire Modular, strengthening Qualcomm Technologies’ software foundation for generative and agentic AI across data center and edge environments.

Gaxos (NASDAQ:GXAI) completed the sale of its gaming assets, including mobile games and Gaxos Gaming Labs, to privately held Game Foundry AI in an all-stock transaction valued at approximately $1.76 million.

Daan Struyven, co-head of global commodities research at Goldman Sachs, explains the three reasons why oil prices are coming down so quickly following the US and Iran reaching an interim peace agreement and says analysts and investors "underappreciated the flexibility" in global oil markets during the conflict.

PodcastOne (NASDAQ:PODC) reported record fiscal 2026 revenue of $61.7 million, an increase of 18% from the prior year.

Viking Therapeutics (NASDAQ:VKTX) has started a Phase 1 single ascending dose study of VK3019 in healthy adults with a body mass index of 30 or higher.

Cognition Therapeutics (NASDAQ:CGTX) reported FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine (CT1812) for the treatment of psychosis in dementia with Lewy bodies (DLB).

ADC Therapeutics (NYSE:ADCT) announced a strategic reorganization aimed at prioritizing its ZYNLONTA franchise and advancing key clinical programs including LOTIS-5 and LOTIS-7.

REGENXBIO (NASDAQ:RGNX) said it has completed dosing in the confirmatory study of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy, marking completion of its registrational development program.